Atossa Therapeutics, Inc. (ATOS) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Atosa Therapeutics Q2 2023 conference call. Please be advised, today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Eric Van Setten, Vice President of Investor and Public Relations. Mr. Van Setten, you may begin. Thank you, Kevin. Good morning, everyone, and welcome to Atosa's second quarter 2023 Corporate and Financial Update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30th, 2023. The press release can be accessed on the investor portion of our website at investors.atosatherapeutics.com. Joining me on the call today are Dr. Stephen Quagg, Atosa's President and Chief Executive Officer, and Greg Weaver, our Executive Vice President and Chief Financial Officer. During today's call, we will be making certain forward-looking statements. which are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. The description of potential risks can be found in our latest SEC disclosure documents and our press release. You're cautioned not to place undue reliance on these forward-looking statements, and ATOSA disclaims any obligation to update these statements. I will now turn the call over to Dr. Quay. Thank you, Eric, and thank you to everyone who joined the call today. I'm very proud of the progress we've made in Q2. From a clinical perspective, each of the three ongoing Phase II trials investigating our proprieta...